The next Teledyne Hanson webinar is going to be held on October 17, 2024. The attendance at the approx 45 minutes long Advances in In Vitro Bioequivalence Assessment for Topical Products – IVRT Focus webinar and the Q&A session is free but registration is needed:
R E G I S T E R |
- The Principal Goal of Bioequivalence (BE)
- Challenges in Topical Generic Drug Development
- Current Approaches and Guidelines for BE of Topical Drug Products in the U.S. and E.U.
- Role of IVRT Method as Surrogate Alternative and Fundamentals of IVRT
- Case Studies
Your expert presenter will be Dr. Theo Kapanadze, co-founder and chief scientific officer of Diteba Inc., a leader in dermal and transdermal research services that has been pivotal in advancing drug development and securing numerous innovator and generic drug approvals. Dr. Kapanadze earned his Ph.D. and D.Sc. in the chemistry of biological active compounds and has 20-plus years of research experience in analytical R&D chemistry and the pharmaceutical, biopharmaceutical, and nutraceutical industries.